Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
JAMA Ophthalmol ; 139(10): 1131-1135, 2021 10 01.
Article in English | MEDLINE | ID: covidwho-1391528

ABSTRACT

Importance: As vaccinations against COVID-19 continue, potential ocular adverse events should be reported in detail to increase awareness among the medical community, although typically, a causal relationship cannot be established definitively. Objective: To describe ocular adverse events that occur soon after receiving an inactivated COVID-19 vaccination (Sinopharm). Design, Setting, and Participants: This case series took place from September 2020 to January 2021 at Cleveland Clinic Abu Dhabi, a tertiary referral center. Patients who reported ocular adverse events and presented within 15 days from the first of 2 doses of an inactivated COVID-19 vaccine were analyzed. Main Outcomes and Measures: Each patient underwent Snellen best-corrected visual acuity that was then converted to logMAR, applanation tonometry, and biomicroscopic examination with indirect ophthalmoscopy. Color fundus photography was obtained with a conventional 9-field fundus photography camera or with a widefield fundus photography system. Optical coherence tomography and optical coherence tomographic angiography images were obtained. Sex, race, age, and clinical data were self-reported. Results: Nine eyes of 7 patients (3 male individuals) presenting with ocular complaints following COVID-19 vaccine were included in the study. The mean (SD) age was 41.4 (9.3) years (range, 30-55 years); the mean best-corrected visual acuity was 0.23 logMAR (range, 0-1 logMAR; approximate Snellen equivalent, 20/32). The mean time of ocular adverse event manifestations was 5.2 days (range, 1-10 days). One patient was diagnosed with episcleritis, 2 with anterior scleritis, 2 with acute macular neuroretinopathy, 1 with paracentral acute middle maculopathy, and 1 with subretinal fluid. Conclusions and Relevance: In this case series study of 7 patients, the timing of transient and ocular complications 5.2 days after vaccination with an inactivated COVID-19 vaccine supported an association with the ocular findings, but a causal relationship cannot be established from this study design.


Subject(s)
COVID-19 Vaccines/adverse effects , Eye Diseases/chemically induced , Subretinal Fluid , Vaccination/adverse effects , Adult , COVID-19 Vaccines/administration & dosage , Eye Diseases/diagnosis , Eye Diseases/physiopathology , Female , Humans , Macular Degeneration/chemically induced , Macular Degeneration/diagnosis , Macular Degeneration/physiopathology , Male , Middle Aged , Retrospective Studies , Risk Assessment , Risk Factors , Scleritis/chemically induced , Scleritis/diagnosis , Scleritis/physiopathology , Time Factors , United Arab Emirates , Vaccines, Inactivated/administration & dosage , Vaccines, Inactivated/adverse effects , White Dot Syndromes/chemically induced , White Dot Syndromes/diagnosis , White Dot Syndromes/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL